Tesamorelin

Tesamorelin is offered strictly as a laboratory research reference material for in-vitro and laboratory research use only. It is a fully synthetic 44-residue peptide amide corresponding to a growth hormone-releasing hormone (GHRH) analog scaffold, distinguished from the native GHRH(1-44) sequence by an N-terminal trans-3-hexenoyl acylation on the tyrosine alpha-amino group. This lipophilic modification, together with the D-alanine substitution at position 2, is the structural feature that defines Tesamorelin as a discrete chemical entity within the GHRH analog family and is a common point of interest in analytical method development and stability profiling.

The material is characterized by molecular formula C221H366N72O67S, average molecular weight 5135.87 g/mol, and a monoisotopic mass of 5132.7166 Da, indexed under CAS 218949-48-5, PubChem CID 16137828, and InChIKey QBEPNUQJQWDYKU-BMGKTWPMSA-N. The complete primary structure is Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2, terminating in a C-terminal carboxamide. Notable side-chain features relevant to analytical handling include four arginine residues, two lysines, a single methionine (a potential oxidation-sensitive site), multiple aspartate and glutamate residues that can influence isoelectric behavior, and asparagine positions that are common considerations in deamidation studies.

Tesamorelin is supplied as a white to off-white lyophilized powder from a synthetic source, with purity established at not less than 98% by HPLC and confirmed on a lot-specific Certificate of Analysis. Identity is typically corroborated by orthogonal techniques such as reversed-phase HPLC retention profiling, high-resolution ESI or MALDI mass spectrometry against the monoisotopic mass, and amino-acid or sequence analysis; the SMILES string provided with each lot supports cheminformatics workflows and structure-based database matching.

Published scientific literature has examined Tesamorelin in preclinical research, and the compound serves investigators as a well-defined GHRH-analog reference standard for comparative characterization, chromatographic system suitability, mass-spectrometric identity confirmation, and peptide stability or degradation-pathway studies. PEPTIDE.Power makes no therapeutic, diagnostic, or efficacy claims regarding this material and provides no administration or dosing guidance.

This material is not a drug, supplement, cosmetic, or food, and is not for human or veterinary use, injection, or ingestion. Identity and purity are documented on the lot-specific Certificate of Analysis, available on request.